PBM Capital Group has completed the sale of a majority interest in Breas Medical Group to Fosun Pharma

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–PBM Capital Group has completed the sale of a majority interest in Breas
Medical Group (“Breas”) to Fosun Pharma (“Fosun”), a leading healthcare
company in China. Fosun is publicly listed on the Hong Kong and Shanghai
stock exchanges. PBM Capital will remain a partner with Fosun and both
parties will work together with management to expand Breas.

“Fosun adds scale and will further strengthen Breas’ presence in Asia, a
high growth market,” says Damian deGoa, PBM Capital Managing Director.
“With its 25-year history in Europe, rapid growth in the United States,
and future expansion in China, Breas will have a strong presence in all
major global markets. The prevalence of respiratory conditions like COPD
and sleep apnea, the transition of healthcare from the hospital to the
home, business development opportunities, and the upcoming launch of
Breas’ new ventilation and CPAP products will accelerate future growth.”

Breas is a leading developer, manufacturer, and distributor of homecare
ventilation and sleep apnea devices. Breas is headquartered in
Gothenburg, Sweden, and has 150 employees in multiple locations around
the world.

PBM Capital first invested in this segment as a venture investor in
Human Design Medical. Then PBM Capital acquired Breas Medical AB from GE
Healthcare. PBM Capital made a subsequent acquisition in the United
Kingdom of B&D Electromedical. The three companies, Breas Medical AB,
B&D Electromedical, and Human Design Medical, are all part of the Breas
Medical Group.

About PBM Capital Group

PBM Capital is a healthcare focused private investment group. PBM
Capital looks for opportunities to use its entrepreneurial and
operational experience to make high growth pharmaceutical, molecular
diagnostic, gene therapy, life science, health/wellness, and consumer
product investments. PBM Capital portfolio companies include Dova
Pharmaceuticals, Avexis (NASDAQ: AVXS), Verrica Pharmaceuticals, Xalud
Therapeutics, Quantapore, Archer Dx, and PBM Pharmaceuticals.

Contacts

PBM Capital Group
Sean Stalfort, 434-980-8104
sstalfort@pbmcap.com